$41.28
Live
0.82%
Downside
Day's Volatility :2.73%
Upside
1.92%
58.91%
Downside
52 Weeks Volatility :71.79%
Upside
31.34%
Period | Establishment Labs Holdings Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -11.49% | 3.6% | 0.0% |
6 Months | -13.18% | 10.2% | 0.0% |
1 Year | 24.73% | 19.6% | 0.0% |
3 Years | -45.29% | 16.8% | -23.0% |
Market Capitalization | 1.2B |
Book Value | $1.61 |
Earnings Per Share (EPS) | -3.14 |
Wall Street Target Price | 64.8 |
Profit Margin | -54.97% |
Operating Margin TTM | -21.18% |
Return On Assets TTM | -13.44% |
Return On Equity TTM | -166.58% |
Revenue TTM | 151.4M |
Revenue Per Share TTM | 5.63 |
Quarterly Revenue Growth YOY | -9.2% |
Gross Profit TTM | 106.6M |
EBITDA | -56.4M |
Diluted Eps TTM | -3.14 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.3 |
EPS Estimate Next Year | -1.18 |
EPS Estimate Current Quarter | -0.51 |
EPS Estimate Next Quarter | -0.43 |
What analysts predicted
Upside of 56.98%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 61.2M | ↑ 76.49% |
Net Income | -21.1M | ↓ 39.54% |
Net Profit Margin | -34.47% | ↑ 66.15% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 89.6M | ↑ 46.33% |
Net Income | -38.2M | ↑ 80.82% |
Net Profit Margin | -42.59% | ↓ 8.12% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 84.7M | ↓ 5.46% |
Net Income | -38.1M | ↓ 0.08% |
Net Profit Margin | -45.02% | ↓ 2.43% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 126.7M | ↑ 49.61% |
Net Income | -41.1M | ↑ 7.92% |
Net Profit Margin | -32.47% | ↑ 12.55% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 161.7M | ↑ 27.64% |
Net Income | -75.2M | ↑ 82.82% |
Net Profit Margin | -46.51% | ↓ 14.04% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 165.2M | ↑ 2.13% |
Net Income | -78.5M | ↑ 4.38% |
Net Profit Margin | -47.53% | ↓ 1.02% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 46.5M | ↑ 6.19% |
Net Income | -11.9M | ↓ 11.95% |
Net Profit Margin | -25.67% | ↑ 5.28% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 48.6M | ↑ 4.38% |
Net Income | -16.7M | ↑ 40.22% |
Net Profit Margin | -34.48% | ↓ 8.81% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 38.5M | ↓ 20.71% |
Net Income | -29.3M | ↑ 74.82% |
Net Profit Margin | -76.02% | ↓ 41.54% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 31.6M | ↓ 18.04% |
Net Income | -20.5M | ↓ 29.83% |
Net Profit Margin | -65.09% | ↑ 10.93% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 37.2M | ↑ 17.77% |
Net Income | -16.2M | ↓ 21.13% |
Net Profit Margin | -43.59% | ↑ 21.5% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Revenue | 44.1M | ↑ 18.7% |
Net Income | -17.2M | ↑ 6.04% |
Net Profit Margin | -38.94% | ↑ 4.65% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 116.6M | ↑ 104.17% |
Total Liabilities | 47.1M | ↓ 24.18% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 116.5M | ↓ 0.04% |
Total Liabilities | 76.9M | ↑ 63.35% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 156.4M | ↑ 34.2% |
Total Liabilities | 81.4M | ↑ 5.86% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 139.5M | ↓ 10.78% |
Total Liabilities | 88.8M | ↑ 9.04% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 211.1M | ↑ 51.27% |
Total Liabilities | 219.2M | ↑ 146.93% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 268.6M | ↑ 27.28% |
Total Liabilities | 250.2M | ↑ 14.14% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 209.4M | ↓ 0.81% |
Total Liabilities | 225.4M | ↑ 2.79% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 285.3M | ↑ 36.27% |
Total Liabilities | 230.4M | ↑ 2.25% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 270.5M | ↓ 5.18% |
Total Liabilities | 240.0M | ↑ 4.17% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 268.6M | ↓ 0.7% |
Total Liabilities | 250.2M | ↑ 4.25% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 301.8M | ↑ 12.36% |
Total Liabilities | 244.9M | ↓ 2.13% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 285.1M | ↓ 5.55% |
Total Liabilities | 240.1M | ↓ 1.98% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -33.9M | ↑ 5.99% |
Investing Cash Flow | -5.7M | ↑ 578.22% |
Financing Cash Flow | 81.5M | ↑ 89.63% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -30.0M | ↓ 11.52% |
Investing Cash Flow | -7.8M | ↑ 35.51% |
Financing Cash Flow | 22.8M | ↓ 72.05% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -12.5M | ↓ 58.28% |
Investing Cash Flow | -5.6M | ↓ 28.42% |
Financing Cash Flow | 64.7M | ↑ 183.78% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -27.5M | ↑ 120.08% |
Investing Cash Flow | -7.2M | ↑ 28.85% |
Financing Cash Flow | 4.1M | ↓ 93.73% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -52.2M | ↑ 89.47% |
Investing Cash Flow | -34.8M | ↑ 385.7% |
Financing Cash Flow | 100.3M | ↑ 2374.21% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -20.6M | ↑ 47.07% |
Investing Cash Flow | -4.3M | ↓ 58.98% |
Financing Cash Flow | 1.2M | ↓ 95.26% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -28.2M | ↑ 36.99% |
Investing Cash Flow | -9.0M | ↑ 111.52% |
Financing Cash Flow | 84.5M | ↑ 7042.18% |
Sell
Neutral
Buy
Establishment Labs Holdings Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Establishment Labs Holdings Inc | 4.44% | -13.18% | 24.73% | -45.29% | 124.6% |
Stryker Corporation | 0.83% | 12.78% | 40.21% | 33.69% | 71.83% |
Boston Scientific Corp. | 4.85% | 29.48% | 75.68% | 96.28% | 127.87% |
Edwards Lifesciences Corp. | 4.32% | -19.19% | 1.77% | -39.29% | -7.22% |
Abbott Laboratories | 3.99% | 11.51% | 24.65% | -4.53% | 46.22% |
Medtronic Plc | 2.65% | 14.48% | 27.42% | -24.18% | -13.49% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Establishment Labs Holdings Inc | NA | NA | NA | -2.3 | -1.67 | -0.13 | NA | 1.61 |
Stryker Corporation | 40.15 | 40.15 | 2.64 | 12.01 | 0.19 | 0.07 | 0.01 | 51.86 |
Boston Scientific Corp. | 70.26 | 70.26 | 2.14 | 2.41 | 0.09 | 0.05 | NA | 13.85 |
Edwards Lifesciences Corp. | 27.67 | 27.67 | 3.65 | 2.6 | 0.22 | 0.12 | NA | 12.35 |
Abbott Laboratories | 35.83 | 35.83 | 4.31 | 4.67 | 0.14 | 0.06 | 0.02 | 22.26 |
Medtronic Plc | 30.23 | 30.23 | 1.67 | 5.2 | 0.08 | 0.04 | 0.03 | 37.39 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Establishment Labs Holdings Inc | Buy | $1.2B | 124.6% | NA | -54.97% |
Stryker Corporation | Buy | $137.1B | 71.83% | 40.15 | 16.12% |
Boston Scientific Corp. | Buy | $127.3B | 127.87% | 70.26 | 12.0% |
Edwards Lifesciences Corp. | Buy | $42.3B | -7.22% | 27.67 | 23.74% |
Abbott Laboratories | Buy | $205.1B | 46.22% | 35.83 | 13.65% |
Medtronic Plc | Buy | $115.2B | -13.49% | 30.23 | 12.06% |
Insights on Establishment Labs Holdings Inc
Revenue is up for the last 3 quarters, 31.56M → 44.11M (in $), with an average increase of 15.4% per quarter
Netprofit is down for the last 2 quarters, -16.20M → -17.18M (in $), with an average decrease of 6.0% per quarter
In the last 1 year, Boston Scientific Corp. has given 76.0% return, outperforming this stock by 52.8%
In the last 3 years, Boston Scientific Corp. has given 96.3% return, outperforming this stock by 141.6%
Nantahala Capital Management, LLC
JW Asset Management, LLC
RTW INVESTMENTS, LLC
Brown Advisory Holdings Inc
Findell Capital Management LLC
Capital Research Global Investors
establishment labs is a global, privately held, high-tech medical device and aesthetics company that designs, develops, manufactures and markets an innovative product portfolio consisting of advanced silicone-filled breast and body shaping implants. with more than 30 years of advanced breast implant manufacturing experience, building quality breast implants has always been a natural outcome for establishment labs’ founders and top executives. as a result, motiva implants® has established a level of product innovation that always results in safety. and while we respect our past, we ́re more focused on the present and the future, one that ́s innovative, safe and progressive. we believe that these goals can be achieved by incorporating the current needs and preferences of plastic surgeons and patients into our product design.
Organization | Establishment Labs Holdings Inc |
Employees | 857 |
CEO | Mr. Juan Jose Chacon Quiros |
Industry | Health Technology |
Jpmorgan Betabuilders 1-5 Year Us Aggregate Bd Etf
$41.28
-1.5%
Invesco Bulletshares 2025 Hi
$41.28
-1.5%
Schwab International Dividend Equity Etf
$41.28
-1.5%
Blockchain Coinvestors Acquisition Corp.
$41.28
-1.5%
Allgiant Travel Company
$41.28
-1.5%
Rogers Corp
$41.28
-1.5%
Innovator Intl Developed 10 Buffer Etf - Quarterly
$41.28
-1.5%
Iheartmedia
$41.28
-1.5%
Lightpath Technologies Inc
$41.28
-1.5%